The NABL accreditation under ISO 15189:2022 validates the technical competence of HaystackAnalytics’ central sequencing facility in Navi Mumbai
HaystackAnalytics, a pioneer in genomics-based diagnostics, has earned accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL). The NABL accreditation under ISO 15189:2022 validates the technical competence of HaystackAnalytics’ central sequencing facility in Navi Mumbai across a broad spectrum of next-generation sequencing (NGS)-based diagnostics in both infectious diseases and human genomics.
Under infectious diagnostics, it covers TB-ONE-NGS (drug resistance ), Flu-NGS (NGS-based detection of respiratory pathogens), Infexn-NGS (NGS based detection of bacteria and fungi. Under human genomics, the company is accredited for tests under whole exome sequencing (WES) and pharmacogenomics (PGx). The recognition reinforces HaystackAnalytics’ commitment to scientific and operational excellence, strengthens its credibility among clinicians, research institutions, and global health partners, and marks a key milestone in its mission to deliver high-quality, accessible, and scalable diagnostics solutions aligned with global standards.
“HaystackAnalytics has always prioritised regulatory excellence and quality. Earlier we received ISO13485 and CE-IVD certifications for our manufacturing facility. Further to our commitment to quality, we are now accredited by NABL for our clinical genomics products and services. We will continue to seek other certifications with the aspiration of establishing the highest global standards of quality at HaystackAnalytics,” said Dr Anirvan Chatterjee, Co-founder and CEO, HaystackAnalytics. “In fields like genomics, where clinical impact hinges on accuracy and trust, this certification ensures that we are meeting the highest global standards, right here in India.”
“The accreditation is a pivotal step in our growth journey,” added Gaurav Srivastava, Co-founder & COO, HaystackAnalytics. “It not only boosts clinician and institutional confidence in our solutions but also strengthens our readiness for domestic and global partnerships. It aligns with our mission to make precision diagnostics accessible, applicable, and affordable for all.”
